조기 진단 파킨슨병 환자 최초 약물의 유효성 및 약물 내성 기간에 대한 평가 = Evaluation for Effectiveness and Tolerance Duration of Initial Medication on Untreated Early Parkinson’s Disease

다국어 초록 (Multilingual Abstract)

The aim of this study was to investigate the correlation among age, symptoms and initial medication (IM), and the tolerance duration of IM in Korean people with Parkinson’s disease (PD). We studied 60 patients with untreated early PD who were initially diagnosed in our hospital between Jun 2006 and Sep 2014. We collected data on sex, age at diagnosis, symptom duration until diagnosis, main motor symptoms, frequency and duration of IM through electronic medical records. We divided patients into groups depending on the number of drugs (MONO/COMBI) and whether to contain dopaminergic property (DOPA/NDOPA). We analyzed the correlation between age and symptoms in each two groups and calculated the mean tolerance duration of IM in each of the groups. The mean symptom duration until diagnosis was 12.2 months. The most frequent drug was levodopa formulations (80%) compared to dopamine agonists (58.3%). The number of patients in the COMBI group (63.3%) was more than that in the MONO group (36.7%). Half of the patients in the COMBI group were taking LDF+DA (50%). Except for tremor, no other symptom showed a significant correlation between with IM. The mean tolerance duration of IM was within 200 days. The mean duration for COMBI group (342.7 days) was longer than that for MONO group (209.8 days). Among regimens, the mean tolerance duration of DOPA group (293.3 days) was longer than for NDOPA group (251.4 days). There was no difference in survival curves between any of the two groups. We found that patients experienced symptoms for over a year in Korea. This indicates that diagnosis time is faster than reported in other previous studies. The longest tolerance duration among IM was for dopaminergic combination therapy. More research is needed to design the most appropriate treatment for PD in Korean patients.

참고문헌 (Reference)

1 한국임상약학회, "약물치료학 요약집 2014, 1st ed" 도서출판 신일북스 402-, 2014

2 Szewczyk-Krolikowsk, K, "The influence of age and gender on motor and non-motor features of early Parkinson’s disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort" 20 : 99-, 2014

3 Parkinson study group, "Pramipexole vs. levodopa as initial treatment for Parkinson disease, a randomized controlled study" 284 : 1931-, 2000

4 Miyasaki, J. M, "Practice parameter: initiation of treatment for Parkinson’s disease: An evidence-based review" 58 : 11-, 2002

5 Connolly, B. S, "Pharmacological treatment of Parkinson disease - A Review" 311 : 1670-, 2014

6 Tarsy, D, "Pharmacologic treatment of Parkinson disease"

7 NICE (National Institute for health and Care Excellence guideline), "Parkinson’s disease, NICE guidelines [CG35]"

8 Cheong, H. K., "Nationwide survey on the prevalence of Parkinson’s disease in Korea"

9 The Parkinson Study Group, "Levodopa and the progression of Parkinson’s disease" 351 : 2498-, 2004

10 Fahn, S, "Is levodopa toxic?" 47 : S184-, 1996

11 Tarsy, D, "Initial treatment of Parkinson’s disease" 8 : 224-, 2006

12 "Homepage of Korea Centers for Disease Control and Prevention"

13 Siuda, J, "Early-onset Parkinson's disease due to PINK1p.Q456X mutation - Clinical and functional study" 20 : 1274-, 2014

14 Hauser, R. A, "Early pharmacologic treatment in Parkinson’s disease" 16 : S100-, 2010

15 Pahwa, R, "Early diagnosis of Parkinson’s disease: Recommendations from diagnostic clinical guidelines" 16 : S94-, 2010

16 "EFNS/MDS-ES (European Federation of Neurological Societies/Movement disorder Society-European Section) guidelines :Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease" 20 : 5-, 2013

17 Nutt, J. G, "Diagnosis and initial management of Parkinson’s disease" 353 : 1021-, 2005

18 주민경, "Analysis of Dosage Mutation in PARK2 among Korean Patients with Early-Onset or Familial Parkinson’s Disease" 대한신경과학회 10 (10): 244-248, 2014

19 Fujio, H, "A case report of Parkinson's disease presenting with olfactory disturbance as a primary symptom in the early stage" 117 : 932-, 2014